Literature DB >> 23910807

Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient.

Umit M Sahiner1, S Tolga Yavuz, Muge Gökce, Betul Buyuktiryaki, Ilhan Altan, Selin Aytac, Murat Tuncer, Ayfer Tuncer, Cansin Sackesen.   

Abstract

In hypersensitive reactions to native L-asparaginase, either premedication and desensitization or substitution with polyethylene glycol conjugated asparaginase (PEG-ASP) is preferred. Anaphylaxis with PEG-ASP is rare. An 8-year-old girl and a 2.5-year-old boy, both diagnosed as having acute lymphoblastic leukemia, presented with native L-asparaginase hypersensitivity and substitution with PEG-ASP was preferred. They received a premedication (methylprednisolone, hydroxyzine and ranitidine) followed by desensitization with PEG-ASP infusion. Both patients developed anaphylaxis with peg-asparaginase. These are the first reported cases of anaphylactic reaction to PEG-ASP, despite the application of both premedication and desensitization. Anaphylaxis with PEG-ASP is very rare and premedication and desensitization protocols may not prevent these hypersensitive reactions.
© 2013 The Authors. Pediatrics International © 2013 Japan Pediatric Society.

Entities:  

Keywords:  anaphylaxis; desensitization; hypersensitivity; polyethylene-glycol asparaginase; premedication

Mesh:

Substances:

Year:  2013        PMID: 23910807     DOI: 10.1111/ped.12131

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  6 in total

1.  The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.

Authors:  Troy Z Horvat; Joshua J Pecoraro; Ryan J Daley; Larry W Buie; Amber C King; Raajit K Rampal; Martin S Tallman; Jae H Park; Dan Douer
Journal:  Leuk Res       Date:  2016-08-26       Impact factor: 3.156

2.  Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.

Authors:  Yiwei Liu; Colton A Smith; John C Panetta; Wenjian Yang; Lauren E Thompson; Jacob P Counts; Alejandro R Molinelli; Deqing Pei; Nancy M Kornegay; Kristine R Crews; Hope Swanson; Cheng Cheng; Seth E Karol; William E Evans; Hiroto Inaba; Ching-Hon Pui; Sima Jeha; Mary V Relling
Journal:  J Clin Oncol       Date:  2019-06-12       Impact factor: 44.544

3.  Predicting success of desensitization after pegaspargase allergy.

Authors:  Hope D Swanson; John C Panetta; Patricia J Barker; Yiwei Liu; Hiroto Inaba; Mary V Relling; Ching-Hon Pui; Seth E Karol
Journal:  Blood       Date:  2020-01-02       Impact factor: 22.113

Review 4.  From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.

Authors:  Deborah Woods; Kari Winchester; Alison Towerman; Katie Gettinger; Christina Carey; Karen Timmermann; Rachel Langley; Emily Browne
Journal:  J Pediatr Oncol Nurs       Date:  2017-06-10       Impact factor: 1.636

Review 5.  Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions.

Authors:  János Szebeni; Raj Bawa
Journal:  Biomedicines       Date:  2020-04-08

Review 6.  Allergic reactions against Covıd-19 vaccines

Authors:  Hilal Ünsal; Bülent Enis Şekerel; Ümit Murat Şahiner
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.